Long-term statin therapy and CSF cholesterol levels: Implications for alzheimer's disease

Barbara A. Evans, James E. Evans, Stephen P. Baker, Kevin Kane, Joan Swearer, Douglas Hinerfeld, Richard John Caselli, Ekaterina Rogaeva, Peter St. George-Hyslop, Majaz Moonis, Daniel A. Pollen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background/Aims: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer's disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin. Methods: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E ε4, and in 6 presymptomatic PS1 subjects. Results: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6-7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter. Conclusions: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.

Original languageEnglish (US)
Pages (from-to)519-524
Number of pages6
JournalDementia and Geriatric Cognitive Disorders
Volume27
Issue number6
DOIs
StatePublished - Jul 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cerebrospinal Fluid
Alzheimer Disease
Cholesterol
Apolipoprotein E4
Lipids
Therapeutics
Simvastatin
Brain

Keywords

  • Alzheimer's disease
  • Brain lipids
  • Cerebrospinal fluid cholesterol
  • Statins

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Cognitive Neuroscience

Cite this

Evans, B. A., Evans, J. E., Baker, S. P., Kane, K., Swearer, J., Hinerfeld, D., ... Pollen, D. A. (2009). Long-term statin therapy and CSF cholesterol levels: Implications for alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 27(6), 519-524. https://doi.org/10.1159/000221835

Long-term statin therapy and CSF cholesterol levels : Implications for alzheimer's disease. / Evans, Barbara A.; Evans, James E.; Baker, Stephen P.; Kane, Kevin; Swearer, Joan; Hinerfeld, Douglas; Caselli, Richard John; Rogaeva, Ekaterina; St. George-Hyslop, Peter; Moonis, Majaz; Pollen, Daniel A.

In: Dementia and Geriatric Cognitive Disorders, Vol. 27, No. 6, 07.2009, p. 519-524.

Research output: Contribution to journalArticle

Evans, BA, Evans, JE, Baker, SP, Kane, K, Swearer, J, Hinerfeld, D, Caselli, RJ, Rogaeva, E, St. George-Hyslop, P, Moonis, M & Pollen, DA 2009, 'Long-term statin therapy and CSF cholesterol levels: Implications for alzheimer's disease', Dementia and Geriatric Cognitive Disorders, vol. 27, no. 6, pp. 519-524. https://doi.org/10.1159/000221835
Evans, Barbara A. ; Evans, James E. ; Baker, Stephen P. ; Kane, Kevin ; Swearer, Joan ; Hinerfeld, Douglas ; Caselli, Richard John ; Rogaeva, Ekaterina ; St. George-Hyslop, Peter ; Moonis, Majaz ; Pollen, Daniel A. / Long-term statin therapy and CSF cholesterol levels : Implications for alzheimer's disease. In: Dementia and Geriatric Cognitive Disorders. 2009 ; Vol. 27, No. 6. pp. 519-524.
@article{c319f8f460874d5ea9a51905ab6db13c,
title = "Long-term statin therapy and CSF cholesterol levels: Implications for alzheimer's disease",
abstract = "Background/Aims: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer's disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin. Methods: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E ε4, and in 6 presymptomatic PS1 subjects. Results: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6-7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter. Conclusions: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.",
keywords = "Alzheimer's disease, Brain lipids, Cerebrospinal fluid cholesterol, Statins",
author = "Evans, {Barbara A.} and Evans, {James E.} and Baker, {Stephen P.} and Kevin Kane and Joan Swearer and Douglas Hinerfeld and Caselli, {Richard John} and Ekaterina Rogaeva and {St. George-Hyslop}, Peter and Majaz Moonis and Pollen, {Daniel A.}",
year = "2009",
month = "7",
doi = "10.1159/000221835",
language = "English (US)",
volume = "27",
pages = "519--524",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Long-term statin therapy and CSF cholesterol levels

T2 - Implications for alzheimer's disease

AU - Evans, Barbara A.

AU - Evans, James E.

AU - Baker, Stephen P.

AU - Kane, Kevin

AU - Swearer, Joan

AU - Hinerfeld, Douglas

AU - Caselli, Richard John

AU - Rogaeva, Ekaterina

AU - St. George-Hyslop, Peter

AU - Moonis, Majaz

AU - Pollen, Daniel A.

PY - 2009/7

Y1 - 2009/7

N2 - Background/Aims: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer's disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin. Methods: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E ε4, and in 6 presymptomatic PS1 subjects. Results: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6-7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter. Conclusions: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.

AB - Background/Aims: It is not yet established whether statins (lipophilic or hydrophilic) reduce the risk of Alzheimer's disease and, if so, by differentially modifying brain lipid levels. Our aim was to assess changes in brain cholesterol metabolism as reflected in the cerebrospinal fluid (CSF) before and after treatment with either atorvastatin or simvastatin. Methods: We carried out a longitudinal analysis of CSF cholesterol, lathosterol and 24(S)-hydroxycholesterol before and after treatment with maximum doses of statins in 10 asymptomatic subjects, 8 of whom were heterozygous for apolipoprotein E ε4, and in 6 presymptomatic PS1 subjects. Results: Statins initially reduced CSF lathosterol cholesterol and 24(S)-hydroxycholesterol in both PS1 and non-PS1 subjects reaching a nadir at 6-7 months, followed by a return to baseline at 15 months with an overshoot at 2 years, tending to return to baseline thereafter. Conclusions: Possible long-term protective effects of statins are not likely largely related to the temporally-dependent biphasic effects of statin therapy upon the magnitude and direction of changes in CSF lipid levels and their subsequent return to baseline levels.

KW - Alzheimer's disease

KW - Brain lipids

KW - Cerebrospinal fluid cholesterol

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=66149141822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149141822&partnerID=8YFLogxK

U2 - 10.1159/000221835

DO - 10.1159/000221835

M3 - Article

C2 - 19478483

AN - SCOPUS:66149141822

VL - 27

SP - 519

EP - 524

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 6

ER -